Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.

Published

Journal Article (Review)

Despite recent advances in both technology and molecular targeting, little progress has been made in the management of most malignancies of the brain, especially brain metastases. In an effort to increase the therapeutic ratio of external beam radiation treatments, radiosensitizers and enhancers have been investigated. Motexafin gadolinium is a new drug with radioenhancing properties and a unique mechanism of action that may increase the therapeutic index of whole brain radiotherapy for patients with brain metastases. The rationale for the use of this drug as well as its current and future role as a radiation enhancer in the management of brain tumors is reviewed.

Full Text

Duke Authors

Cited Authors

  • Khuntia, D; Mehta, M

Published Date

  • December 2004

Published In

Volume / Issue

  • 4 / 6

Start / End Page

  • 981 - 989

PubMed ID

  • 15606327

Pubmed Central ID

  • 15606327

Electronic International Standard Serial Number (EISSN)

  • 1744-8328

Digital Object Identifier (DOI)

  • 10.1586/14737140.4.6.981

Language

  • eng

Conference Location

  • England